How did biopharma shape up for 2018 in terms of mergers, acquisitions, and other business deals? Explore what transpired during last year for M&A in biopharma, when tax cuts were expected to spur major activity. In Vivo brings you a vital look back at the events of 2018.
Author: Amanda Micklus
Published: 14 January 2019
Number of pages:6
Which major deals marked 2018 M&A, a year during which the industry had high expectations for deal activity, given the anticipation of favorable tax breaks in the US? Explore what deals and companies showed the most activity, take a look at the year’s biggest deals and areas of interest, and understand the trends that 2018’s M&A deals may indicate for the future with this informative look at the market from In Vivo. Covered is a look at in-licensing, acquisitions, top deals by therapeutic area, and IPO and VP investment in various therapeutic areas.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.